In summary, we have shown that TSA, a potent pan-HDAC inhibitor, significantly improves the phenotype caused by Smn deficiency in the Smn2B/- intermediate mouse model of SMA. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.